Ionis Pharmaceuticals, Inc. Proceeds from Debt, Net of Issuance Costs
Ionis Pharmaceuticals, Inc. (IONS) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2020-03-02
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2018-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2017-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2016-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2019 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2017 was $59.75M.
- Ionis Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2016 was $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $59.75M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $59.75M 10-Q · filed 2018-11-06 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |